Efficacy of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists on proteinuria and weight in a diabetes cohort

Table 2 Baseline characteristics of the sodium-glucose cotransporter-2 inhibitor group and control group, n (%)

Variables	SGLT2i group (n = 387)	Control group (n = 774)	P value
Age (years)	56.26 ± 11.56	56.07 ± 12.47	0.992
Sex (male/female, male %)	256/131, 66.15	511/263, 66.02	0.987
Duration of diabetes (years)	9.20 ± 7.82	9.06 ± 8.29	0.334
FBG (mmol/L)	7.92 ± 1.97	7.88 ± 1.88	0.675
2hPBG (mmol/L)	8.94 ± 2.39	8.75 ± 2.52	0.367
HbA1c (%)	6.85 ± 0.98	6.66 ± 1.02	< 0.001
UACR (mg/g)	96.82 ± 299.39	50.54 ± 257.55	< 0.001
eGFR (mL/min/1.73 m2)	85.79 ± 19.33	85.46 ± 19.48	0.534
Body weight (kg)	73.38 ± 12.88	71.16 ± 12.43	0.017
BMI (kg/m2)	25.68 ± 3.47	25.08 ± 3.48	0.007
UACR grades
< 30 mg/g	156 (65.82)	269 (83.80)	0.009
30-300 mg/g	19 (8.02)	9 (2.80)
> 300 mg/g	62 (26.16)	43 (13.40)
BMI grades
18-24 kg/m2	4 (1.04)	6 (1.13)	0.143
24-28 kg/m2	115 (29.79)	194 (36.47)
28-35 kg/m2	183 (47.41)	239 (44.92)
> 35 kg/m2	84 (21.76)	93 (17.48)

FBG: Fasting blood glucose; PBG: Prandial blood glucose; HbA_1c: Glycosylated hemoglobin; UACR: Urinary albumin-creatinine ratio; eGFR: Estimated glomerular filtration rate; BMI: Body mass index; SGLT2i: Sodium-glucose cotransporter-2 inhibitor.